News

In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms – demonstrating a statistically significant decrease in 24-hour coughs per

Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based coronavirus vaccine for the prevention of COVID-19 infection. The vaccine will not be supplied

Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2). The early-stage study

The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclinical Module and

The CVR represents additional consideration upon XERAVA™ (eravacycline for injection) achieving certain net sales starting in 2021.  The acquisition is consistent with AcelRx’s strategic plan to expand and

AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of the body. The FDA has provided the

Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company’s growing Contract Development

The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in a mammalian cell model system as

The later stage trial has been evaluating avelumab plus chemoradiotherapy (CRT) in comparison to standard-of-care CRT in patients having untreated locally advanced squamous cell carcinoma of the head